Pulmonx Corporation (LUNG)

Market Cap	271.41M
Revenue (ttm)	83.79M
Net Income (ttm)	-56.39M
Shares Out	39.80M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	295,171
Open	6.76
Previous Close	6.79
Day's Range	6.47 - 7.02
52-Week Range	5.46 - 10.01
Beta	0.51
Analysts	Strong Buy
Price Target	12.64 (+85.34%)
Earnings Date	Apr 30, 2025

About LUNG

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with mult...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 1, 2020
• Employees: 291
• Stock Exchange: NASDAQ
• Ticker Symbol: LUNG
• Website: https://pulmonx.com

Financial Performance

In 2024, Pulmonx's revenue was $83.79 million, an increase of 22.01% compared to the previous year's $68.68 million. Losses were -$56.39 million, -7.31% less than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for LUNG stock is "Strong Buy." The 12-month stock price forecast is $12.64, which is an increase of 85.34% from the latest price.

Price Target

$12.64

(85.34% upside)

Analyst Consensus: Strong Buy